Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial. - Chen, Xinni; Wang, Feng; Cheng, Yuan; Cao, Mengran; Mei, Kuimin; Chu, Xiaoyuan; Dai, Fang; Gong, Xinlei (Clinical & Translational Discovery, 2026)